ArticleQatar medical journal2025
Clinical outcome and cost of intravenous, OPAT, and oral treatment of Gram-negative bacteremia.
Article in Qatar medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Outpatient Parenteral Antimicrobial Therapy in Asia: Evolution, Models, and Challenges over the Past Decade-A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gram-negative bacteremia (GNB) causes substantial morbidity, mortality, prolonged hospitalization, and readmissions worldwide. Standard practice recommends initial intravenous (IV) antibiotics, but many clinically stable patients now complete therapy through outpatient parenteral antimicrobial therapy (OPAT), which may improve antimicrobial stewardship and reduce costs. This study aims to compare clinical and economic outcomes of inpatient versus OPAT-managed GNB. Methods: We conducted a retrospective observational cohort study of all adults with GNB treated at a 320-bed general hospital from July 2021 to July 2022. We excluded patients younger than 18 years, blood culture contaminants, and patients with Gram-positive or mixed infections. Patients were assigned to four final treatment pathways: inpatient IV only, hospital-based OPAT IV room (OPAT-IV), home-based IV therapy (Home-IV), or early oral switch. Primary outcomes were 30-day mortality and bacteremia recurrence; secondary outcomes were length of stay and treatment cost. Results: We identified 125 patients (mean age, 56 years; 51.2% female). Most isolates originated from urinary (54.4%) or intra-abdominal (23%) sources. Pan-sensitive organisms accounted for 57.6% of cases; extended-spectrum β-lactamase producers, 35.2%; and multidrug-resistant organisms, 7.2%. Thirty-seven patients (29.6%) completed IV therapy as inpatients, 16 (12.8%) in OPAT-IV, 13 (10.4%) in Home-IV, and 59 (47%) were discharged on oral antibiotics. Nine deaths (24.3%) occurred in the inpatient group and one (7.7%) in Home-IV; no deaths occurred in OPAT-IV or oral-therapy groups. Readmissions within 90 days were uncommon (≤7.7% across groups). Mean antibiotic durations were 13.0 days (inpatient), 11.3 days (OPAT-IV), 10.6 days (Home-IV), and 7.7 days (oral). OPAT pathways shortened hospital stays and reduced drug and bed-day costs. Conclusion: OPAT provided safe, effective treatment for selected patients with GNB, lowering mortality, shortening length of stay, and reducing costs compared with continued inpatient care. Careful patient selection and early IV-to-oral transition can maximize these benefits while maintaining favorable clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.